Comment: Barbiturates may well increase adverse effects, which include respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.

pentobarbital will lessen the level or effect of ondansetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. No dosage adjustment for ondansetron is suggested for individuals on these drugs.

pentobarbital will decrease the level or outcome of estrogens esterified by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

pentobarbital will decrease the extent or outcome of etravirine by impacting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Watch.

pentobarbital will decrease the level or influence of bosentan by influencing hepatic enzyme CYP2C9/10 metabolism. Minimal/Significance Not known.

Contraindicated (one)pentobarbital will lessen the level or influence of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will reduce the extent or effect of bortezomib by affecting hepatic/intestinal read more enzyme CYP3A4 metabolism. Use Caution/Monitor.

Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer might minimize doravirine plasma concentrations and/or effects. Probable for lack of virologic response and attainable resistance to doravirine.

pentobarbital will reduce the level or impact of hydrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital will reduce the extent or outcome of armodafinil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.

Too swift administration might lead to respiratory despair, laryngospasm, apnea, or vasodilation with fall in blood pressure level

pentobarbital decreases effects of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Intently. Coadministration of CYP3A4 inducers may perhaps reduce sufentanil stages and efficacy, probably precipitating withdrawal syndrome in sufferers who've created Bodily dependence to sufentanil. Discontinuation of concomitantly used CYP3A4 inducers may improve sufentanil plasma concentration.

Check Closely (one)pentobarbital will decrease the level or result of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will lessen the level or outcome of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. Lack of, or lessened reaction to tofacitinib may well happen when coadministered with strong CYP3A4 inducers